![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessHaemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients
Haemophagocytic lymphohistiocytosis (HLH) is a syndrome that occurs in patients with severe systemic hyperinflammation. GATA binding protein 2 (GATA2) is a transcription factor and key component in haematopoiesis...
-
Article
Progesterone induces glioblastoma cell apoptosis by coactivating extrinsic and intrinsic apoptotic pathways
Glioblastoma is a common and lethal primary brain tumor with a mean survival time less than 2 years. Progesterone, a natural steroid hormone, is a small molecule with distinct effects on glioblastoma cells. Hi...
-
Article
STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1
Oncolytic viruses are emerging as promising anticancer agents. Although the essential biological function of N-glycosylation on viruses are widely accepted, roles of N-glycan and glycan-processing enzyme in on...
-
Article
Open AccessDirected natural evolution generates a next-generation oncolytic virus with a high potency and safety profile
Oncolytic viruses (OVs) represent a type of encouraging multi-mechanistic drug for the treatment of cancer. However, attenuation of virulence, which is generally required for the development of OVs based on pa...
-
Article
Open AccessIdentification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors
Over the last decade, oncolytic virus (OV) therapy has shown its promising potential in tumor treatment. The fact that not every patient can benefit from it highlights the importance for defining biomarkers th...
-
Article
Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC
Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype among breast tumors and remains a challenge even for the most current therapeutic regimes. Here, we demonstrate that oncolytic alph...